e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

4.898 +0.148 (+3.11%)

Streaming Delayed Price Updated: 11:34 AM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma ↗

April 11, 2022

Via Benzinga

Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers ↗

March 16, 2022

Via Benzinga

Recap: Cellectis Q4 Earnings ↗

March 03, 2022

Cellectis (NASDAQ:CLLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cellectis...

Via Benzinga

A Preview Of Cellectis's Earnings ↗

March 02, 2022

Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

30 Stocks Moving In Tuesday's Mid-Day Session ↗

January 11, 2022

Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year....

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

January 11, 2022

Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

FDA Lifts Clinical Hold On Allogene's CAR-T Trials ↗

January 11, 2022

The FDA has lifted the hold on Cellectis SA's (NASDAQ: CLLS) licensed partner, Allogene Therapeutics Inc (NASDAQ: ALLO) clinical trials. The...

Via Benzinga

21 Stocks Moving in Tuesday's Pre-Market Session ↗

January 11, 2022

Gainers OneSmart International Education Group Limited (NYSE: ONE) rose 39.1% to $0.2701 in pre-market trading. OneSmart International Education Group received notification from...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗

January 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022 ↗

January 06, 2022

Upgrades For Canada Goose Holdings Inc (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 21, 2021

Gainers BioRestorative Therapies (NASDAQ:BRTX...

Via Benzinga

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China ↗

November 19, 2021

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The...

Via Benzinga

Cellectis SA (CLLS) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

CLLS earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

44 Biggest Movers From Yesterday ↗

October 15, 2021

Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021 ↗

November 30, 2021

Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ:

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 14, 2021

Gainers NRX Pharmaceuticals (NASDAQ:NRXP...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 13, 2021

Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 11, 2021

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at...

Via Benzinga

15 Stocks Moving in Monday's Pre-Market Session ↗

October 11, 2021

Gainers Trevi Therapeutics, Inc. (NASDAQ: TRVI) rose 32.5% to $1.59 in pre-market trading after the company filed Friday to withdraw its offering of shares. Nutriband Inc. (...

Via Benzinga

35 Biggest Movers From Friday ↗

October 11, 2021

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for...

Via Benzinga

Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher ↗

October 08, 2021

Toward the end of trading Friday, the Dow traded up 0.24% to 34,835.06 while the NASDAQ fell 0.13% to 14,635.04. The S&P also rose, gaining 0.13% to 4,405.69. The U.S. has the...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 08, 2021

Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6...

Via Benzinga

Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge ↗

October 08, 2021

Midway through trading Friday, the Dow traded down 0.06% to 34,734.52 while the NASDAQ fell 0.25% to 14,617.60. The S&P also fell, dropping 0.08% to 4,396.09. The U.S. has the...

Via Benzinga

Topics Stocks

28 Stocks Moving In Friday's Mid-Day Session ↗

October 08, 2021

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021 ↗

October 08, 2021

Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ:

Via Benzinga

Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September ↗

October 08, 2021

Following the market opening Friday, the Dow traded up 0.12% to 34,796.95 while the NASDAQ rose 0.09% to 14,667.44. The S&P also rose, gaining 0.16% to 4,406.93. The U.S. has...

Via Benzinga

Topics Economy Stocks

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy